Tags

Type your tag names separated by a space and hit enter

Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
J Ocul Pharmacol Ther 2010; 26(2):207-12JO

Abstract

PURPOSE

To investigate the effect of intravitreal bevacizumab (IVB) combined with intravitreal high-dose triamcinolone acetonide (IVTA) for therapy of exudative age-related macular degeneration (AMD) after unsuccessful IVB monotherapy.

METHODS

The prospective study included 29 White patients (31 eyes) who consecutively received IVB (1.5 mg) plus high-dose IVTA (20-25 mg) for exudative AMD, after they had received multiple IVB mono-injections without functional and anatomical success. Two additional IVB injections were given in intervals of 2 months after the combined injection. The main outcome parameters were best-corrected visual acuity (BCVA) and data measured by optic coherence tomography (OCT).

RESULTS

Mean BCVA (LogMAR) improved from 0.70 + or - 0.37 LogMAR at baseline to 0.59 + or - 0.38 LogMAR at 2 months after first follow-up (P = 0.004) and to 0.63 + or - 0.41 LogMAR (P = 0.04) at 4 months after baseline. It deteriorated to 0.68 + or - 0.41 at the end of the follow-up at 7 months after the combined injection, without a significant (P = 0.53) difference to the baseline visual acuity. The maximum macular thickness decreased significantly from 371 + or - 206 microm at baseline to 322 + or - 90 microm (P = 0.04) at the first follow-up and to 316 + or - 90 microm (P = 0.03) at the second follow-up. It slightly increased toward the end of follow-up (333 + or - 133 microm; P = 0.16). Intraocular pressure increased marginally significantly (P = 0.06) from 14.5 + or - 2.8 mm Hg to 15.7 + or - 3.3 mm Hg at the second follow-up.

CONCLUSIONS

Patients with exudative AMD, in whom monotherapy with IVB was unsuccessful, may experience a temporary improvement in vision and reduction in macular thickness after a combined intravitreal injection of bevacizumab and triamcinolone.

Authors+Show Affiliations

Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University, Heidelberg, Germany.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20415625

Citation

Tao, Yong, and Jost B. Jonas. "Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for Therapy-resistant Exudative Age-related Macular Degeneration." Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, vol. 26, no. 2, 2010, pp. 207-12.
Tao Y, Jonas JB. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration. J Ocul Pharmacol Ther. 2010;26(2):207-12.
Tao, Y., & Jonas, J. B. (2010). Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, 26(2), pp. 207-12. doi:10.1089/jop.2009.0131.
Tao Y, Jonas JB. Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for Therapy-resistant Exudative Age-related Macular Degeneration. J Ocul Pharmacol Ther. 2010;26(2):207-12. PubMed PMID: 20415625.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration. AU - Tao,Yong, AU - Jonas,Jost B, PY - 2010/4/27/entrez PY - 2010/4/27/pubmed PY - 2010/9/8/medline SP - 207 EP - 12 JF - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics JO - J Ocul Pharmacol Ther VL - 26 IS - 2 N2 - PURPOSE: To investigate the effect of intravitreal bevacizumab (IVB) combined with intravitreal high-dose triamcinolone acetonide (IVTA) for therapy of exudative age-related macular degeneration (AMD) after unsuccessful IVB monotherapy. METHODS: The prospective study included 29 White patients (31 eyes) who consecutively received IVB (1.5 mg) plus high-dose IVTA (20-25 mg) for exudative AMD, after they had received multiple IVB mono-injections without functional and anatomical success. Two additional IVB injections were given in intervals of 2 months after the combined injection. The main outcome parameters were best-corrected visual acuity (BCVA) and data measured by optic coherence tomography (OCT). RESULTS: Mean BCVA (LogMAR) improved from 0.70 + or - 0.37 LogMAR at baseline to 0.59 + or - 0.38 LogMAR at 2 months after first follow-up (P = 0.004) and to 0.63 + or - 0.41 LogMAR (P = 0.04) at 4 months after baseline. It deteriorated to 0.68 + or - 0.41 at the end of the follow-up at 7 months after the combined injection, without a significant (P = 0.53) difference to the baseline visual acuity. The maximum macular thickness decreased significantly from 371 + or - 206 microm at baseline to 322 + or - 90 microm (P = 0.04) at the first follow-up and to 316 + or - 90 microm (P = 0.03) at the second follow-up. It slightly increased toward the end of follow-up (333 + or - 133 microm; P = 0.16). Intraocular pressure increased marginally significantly (P = 0.06) from 14.5 + or - 2.8 mm Hg to 15.7 + or - 3.3 mm Hg at the second follow-up. CONCLUSIONS: Patients with exudative AMD, in whom monotherapy with IVB was unsuccessful, may experience a temporary improvement in vision and reduction in macular thickness after a combined intravitreal injection of bevacizumab and triamcinolone. SN - 1557-7732 UR - https://www.unboundmedicine.com/medline/citation/20415625/Intravitreal_bevacizumab_combined_with_intravitreal_triamcinolone_for_therapy_resistant_exudative_age_related_macular_degeneration_ L2 - https://www.liebertpub.com/doi/full/10.1089/jop.2009.0131?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -